MCL Clinical Trials

1230 trials from ClinicalTrials.gov. Recruiting trials shown first.

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

NCT01460134·PHASE1·Celldex Therapeutics·90 enrolled

CDX-1127CDX-1127CDX-1127

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

NCT01403636·PHASE2·Sanofi·167 enrolled

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

NCT01397591·PHASE2·OHSU Knight Cancer Institute·3 enrolled

OfatumumabBortezomib

Study of Mantle Cell Lymphoma Treatment by RiBVD

NCT01457144·PHASE2·French Innovative Leukemia Organisation·76 enrolled

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

NCT01435720·PHASE1 / PHASE2·Senesco Technologies, Inc.·15 enrolled

SNS01-TSNS01-TSNS01-TSNS01-T

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

NCT01427881·PHASE2·Fred Hutchinson Cancer Center·43 enrolled

cyclophosphamidecyclosporineperipheral blood stem cell transplantationtotal-body irradiationfludarabine phosphate+2 more

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

NCT01437709·PHASE2·Memorial Sloan Kettering Cancer Center·30 enrolled

Ofatumumab (This arm is closed)Ofatumumab + Bendamustine

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

NCT01397825·PHASE1 / PHASE2·Millennium Pharmaceuticals, Inc.·45 enrolled

Alisertib (MLN8237)RituximabVincristine

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

NCT01472562·PHASE2·Weill Medical College of Cornell University·38 enrolled

lenalidomiderituximab

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

NCT01381692·PHASE1 / PHASE2·National Cancer Institute (NCI)·9 enrolled

BortezomibDexamethasoneLaboratory Biomarker AnalysisQuality-of-Life AssessmentRituximab+1 more

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

NCT01326702·PHASE1 / PHASE2·National Cancer Institute (NCI)·43 enrolled

Bendamustine HydrochloridePharmacological StudyRituximabVeliparib

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

NCT02037256·NA·Barbara Ann Karmanos Cancer Institute·23 enrolled

bortezomibfilgrastimautologous hematopoietic stem cell transplantation

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

NCT01399840·PHASE1·Pfizer·33 enrolled

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

NCT00968760·PHASE1·M.D. Anderson Cancer Center·34 enrolled

LeukapheresisStem Cell TransplantCD19-specific T Cell InfusionIL-2Carmustine+3 more

Imexon for Relapsed Follicular and Aggressive Lymphomas

NCT01314014·PHASE2·University of Rochester·22 enrolled

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

NCT01345357·PHASE1·Cephalon·24 enrolled

CEP-9722GemcitabineCisplatin

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

NCT01658319·PHASE1·Case Comprehensive Cancer Center·20 enrolled

fludarabine phosphatemethoxyaminelaboratory biomarker analysispharmacological studywestern blotting+2 more

AMG 319 Lymphoid Malignancy FIH

NCT01300026·PHASE1·Amgen·28 enrolled

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

NCT01504776·PHASE1·Anand Jillella·3 enrolled

PanobinostatBortezomib

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

NCT01562977·PHASE2·Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea·82 enrolled

Rituximab, Gemcitabine, Oxaliplatin, Dexametasone

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

NCT01180049·PHASE4·Pfizer·101 enrolled

temsirolimustemsirolimus

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

NCT01322776·PHASE1 / PHASE2·Sun Yat-sen University·40 enrolled

Combination of Bortezomib, Fludarabine and Cyclophosphamide

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

NCT01236391·PHASE2·Pharmacyclics LLC.·115 enrolled

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

NCT01484015·PHASE1·Wake Forest University Health Sciences·70 enrolled

cefepime hydrochloride

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT01261247·PHASE2·Mayo Clinic·41 enrolled

panobinostatlaboratory biomarker analysiswestern blottingDNA analysisflow cytometry+2 more

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

NCT01075321·PHASE1 / PHASE2·Mayo Clinic·58 enrolled

everolimuslenalidomidelaboratory biomarker analysispolymorphism analysisimmunohistochemistry staining method+2 more

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00448201·PHASE2·UNC Lineberger Comprehensive Cancer Center·71 enrolled

anti-thymocyte globulinsargramostimtherapeutic allogeneic lymphocytesbusulfanfludarabine phosphate+4 more

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01231919·PHASE1·National Cancer Institute (NCI)·45 enrolled

Akt inhibitor MK2206diagnostic laboratory biomarker analysispharmacological study

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

NCT01367457·Pfizer·243 enrolled

Temsirolimus (Non-Interventional Study)

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

NCT01273766·PHASE2·Wake Forest University Health Sciences·16 enrolled

deferasiroxlaboratory biomarker analysisenzyme-linked immunosorbent assay

← PreviousPage 19 of 41Next →